Thymosin Beta-4
Peptide ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Thymosin Beta-4 is an endogenous 43-amino-acid peptide involved in actin regulation, cell migration, angiogenesis, and tissue repair. It is not FDA-approved as a systemic injectable drug; ophthalmic thymosin beta-4 formulations have been studied but remain investigational in the United States. Evidence is strongest for topical or ophthalmic research contexts, not wellness injection protocols.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Thymosin Beta-4 is a peptide most often used for studied for ocular surface healing, supports cell migration in repair models, investigational wound-healing biology. NutriStack rates the overall evidence as emerging. A typical adult dose is No FDA-approved systemic human dose; ophthalmic trial dosing has used studied eye-drop protocols, commonly taken as investigational ophthalmic or clinical-trial product only; avoid research-grade injections. This profile indexes 3 sources.
- Injection-site reaction
- Headache
- Fatigue
- Active malignancy or unexplained mass without oncology clearance
- Pregnancy and breastfeeding
The bottom line
Evidence rating emerging. Most-documented uses: studied for ocular surface healing, supports cell migration in repair models, investigational wound-healing biology. 3 sources indexed (2010–2022), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Thymosin beta-4 binds G-actin and helps regulate actin polymerization, supporting epithelial and endothelial cell migration during repair. It also influences inflammatory signaling, apoptosis, angiogenesis, and extracellular matrix remodeling in preclinical models. These effects do not establish that unregulated TB-500 or systemic peptide products are safe or effective for injury recovery.1,2
Dosing & protocol.
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.2
What it actually costs.
Real-world pricing across three quality tiers. Assumes Investigational Ophthalmic Solution.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Full safety detail.
Side effects
- Injection-site reaction
- Headache
- Fatigue
- Unknown long-term angiogenesis effects
- Contamination risk from research products
- Possible eye irritation with topical ocular formulations
Contraindications
- Active malignancy or unexplained mass without oncology clearance
- Pregnancy and breastfeeding
- Use for acute tendon rupture or serious wound without medical care
- Non-FDA-approved systemic injection2
- Known hypersensitivity to formulation ingredients
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
2- 1Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment modelSosne G et al. · Clinical Ophthalmology · 2015
Primary endpoints were mixed
- 2A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteersRuff D et al. · Annals of the New York Academy of Sciences · 2010
No dose-limiting toxicity was reported
Reviews & position papers
1- 3Research advances on thymosin beta4 in promoting wound healingGao YX et al. · Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi · 2022
Angiogenic and anti-inflammatory mechanisms were reviewed
Common questions.
Quick answers about Thymosin Beta-4, drawn from the data on this page.
What is Thymosin Beta-4?
Thymosin Beta-4 is an endogenous 43-amino-acid peptide involved in actin regulation, cell migration, angiogenesis, and tissue repair. It is not FDA-approved as a systemic injectable drug; ophthalmic thymosin beta-4 formulations have been studied but remain investigational in the United States. Evidence is strongest for topical or ophthalmic research contexts, not wellness injection protocols.
What is Thymosin Beta-4 used for?
Commonly cited benefits of Thymosin Beta-4 include: Studied for ocular surface healing; Supports cell migration in repair models; Investigational wound-healing biology; No FDA-approved systemic wellness use. NutriStack rates the overall evidence as emerging.
What is a typical dose of Thymosin Beta-4?
A typical adult dose of Thymosin Beta-4 is No FDA-approved systemic human dose; ophthalmic trial dosing has used studied eye-drop protocols. The commonly recommended form is Investigational ophthalmic or clinical-trial product only; avoid research-grade injections. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Thymosin Beta-4?
Reported side effects include injection-site reaction, headache, fatigue, unknown long-term angiogenesis effects, contamination risk from research products, possible eye irritation with topical ocular formulations. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Thymosin Beta-4?
NutriStack rates this as Emerging, meaning early RCT signal, mechanistic data, or limited human evidence. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Thymosin Beta-4 in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.